Last reviewed · How we verify
NCT05912179
Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
trial testing Liver biopsy - percutaneous in Liver Diseases in 200 participants. Status unknown.
30 September 2023
Quick facts
| Lead sponsor | Nottingham University Hospitals NHS Trust |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 1 September 2022 |
| Primary completion | 30 September 2023 |
| Estimated completion | 30 September 2023 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Liver biopsy - percutaneous
- Liver biopsy - transjugular
- liver biopsy - EUS guided
Conditions studied
- Liver Diseases — all drugs for Liver Diseases →
- Liver Fibrosis — all drugs for Liver Fibrosis →
Sponsor
Nottingham University Hospitals NHS Trust
Who can join
Adults 18 to 100, any sex, with Liver Diseases or Liver Fibrosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to learn about endoscopic ultrasound(EUS) guided liver biopsy and how this compares to traditional methods of obtaining liver biopsy samples, in patients with liver disease. The main questions it aims to answer are: 1. is EUS liver biopsy equally as good as other types of techniques 2. are there any advantages to using the EUS technique to obtain liver biopsies Researchers will compare data from patients who have had a liver biopsy with a traditional technique with those who have undergone EUS-guided biopsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05912179
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Diseases
Currently open trials in the same condition.
- NCT07400289 — Development of a FibroScan Liver Examination Using a Single Probe · NA · recruiting
- NCT07150624 — The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine · Phase 4 · recruiting
- NCT06871111 — The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial · Phase 1 · recruiting
- NCT06874296 — Assessing Declined Liver Grafts With Normothermic Machine Perfusion to Reduce Transplant Waiting Time · NA · recruiting
- NCT07053488 — CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection · Phase 1, PHASE2 · recruiting
Other Nottingham University Hospitals NHS Trust trials
Trials by the same sponsor.
- NCT07350408 — Mapping Post-falls Organisational Processes in Care Homes · recruiting
- NCT07036081 — A Single Arm Intervention Study to Assess the Acceptability, Tolerance and Ease of Use of Wilbo's Blends+ (Commercial En · NA · completed
- NCT07303569 — Prevention of Pressure Injury (PI) in Hospitalised Infants, Children, and Young People (CYP) (Aged 0-19 Years) · recruiting
- NCT06572345 — Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study · NA · recruiting
- NCT07136298 — Seizure Identification on the Intensive Care Unit (ICU) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05912179 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nottingham University Hospitals NHS Trust
- Last refreshed: 22 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05912179.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing